Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2024 Filed Aug 19, 2024 21:28 UTC |
Bohnen ShaneSVP - General Counsel
|
GrantStock Option (Right to Buy) · Derivative | 13,488 | $0.00 Strike: $74.91 | $0.00 |
DisclosureSEC source: 0001062993-24-015382 · form4.xml · derivative · entry 15 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,488 Underlying: Common Stock · 13,488 shares Expires 2034-08-15 F12 · derivative.exercise_date: Options to purchase 3,372 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:28 UTC |
Bohnen ShaneSVP - General Counsel
|
GrantRestricted Stock Units · Derivative | 5,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015382 · form4.xml · derivative · entry 14 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,006 Underlying: Common Stock · 5,006 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: 1,668 restricted stock units vest on 8/15/2025, and 1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027. F11 · derivative.expiration_date: 1,668 restricted stock units vest on 8/15/2025, and 1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:28 UTC |
Bohnen ShaneSVP - General Counsel
|
GrantPerformance Restricted Stock Units · Derivative | 10,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015382 · form4.xml · derivative · entry 13 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,012 Underlying: Common Stock · 10,012 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F10 · derivative.expiration_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:28 UTC |
Bohnen ShaneSVP - General Counsel
|
Exercise / conversionRestricted Stock Units · Derivative | 49 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015382 · form4.xml · derivative · entry 10 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99 Underlying: Common Stock · 49 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F8 · derivative.exercise_date: 49 restricted stock units vest on 8/15/2024 and 8/15/2026, and 50 restricted stock units vest on 8/15/2025 F8 · derivative.expiration_date: 49 restricted stock units vest on 8/15/2024 and 8/15/2026, and 50 restricted stock units vest on 8/15/2025 Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:28 UTC |
Bohnen ShaneSVP - General Counsel
|
Tax withholdingCommon Stock | 15 | $74.91 | $1,123.65 |
DisclosureSEC source: 0001062993-24-015382 · form4.xml · nonDerivative · entry 2 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,681 Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:28 UTC |
Bohnen ShaneSVP - General Counsel
|
Exercise / conversionCommon Stock | 49 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015382 · form4.xml · nonDerivative · entry 1 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:27 UTC |
McManus MatthewPresident - DGS
|
GrantStock Option (Right to Buy) · Derivative | 21,320 | $0.00 Strike: $74.91 | $0.00 |
DisclosureSEC source: 0001062993-24-015380 · form4.xml · derivative · entry 7 McManus Matthew · CIK 0001908268 · President - DGS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,320 Underlying: Common Stock · 21,320 shares Expires 2034-08-15 F7 · derivative.exercise_date: Options to purchase 5,330 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:27 UTC |
McManus MatthewPresident - DGS
|
GrantRestricted Stock Units · Derivative | 7,912 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015380 · form4.xml · derivative · entry 6 McManus Matthew · CIK 0001908268 · President - DGS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,912 Underlying: Common Stock · 7,912 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F6 · derivative.exercise_date: 2,637 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 2,638 restricted stock units vest on 8/15/2027. F6 · derivative.expiration_date: 2,637 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 2,638 restricted stock units vest on 8/15/2027. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:27 UTC |
McManus MatthewPresident - DGS
|
GrantPerformance Restricted Stock Units · Derivative | 15,818 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015380 · form4.xml · derivative · entry 5 McManus Matthew · CIK 0001908268 · President - DGS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,818 Underlying: Common Stock · 15,818 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F5 · derivative.exercise_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F5 · derivative.expiration_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2024 Filed Feb 3, 2025 21:38 UTC Amendment |
McManus MatthewPresident - DGS
|
GrantPerformance Restricted Stock Units · Derivative | 15,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-001501 · form4a.xml · derivative · entry 1 McManus Matthew · CIK 0001908268 · President - DGS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,825 Underlying: Common Stock · 15,825 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:08 UTC |
BAUMGARTNER ROBERT VDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $22.95 | $0.00 |
DisclosureSEC source: 0001062993-24-014847 · form4.xml · derivative · entry 3 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2024-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:08 UTC |
BAUMGARTNER ROBERT VDirector
|
SaleCommon Stock | 16,000 | $72.10 | $1,153,664.00 |
DisclosureSEC source: 0001062993-24-014847 · form4.xml · nonDerivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,401 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.33 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:08 UTC |
BAUMGARTNER ROBERT VDirector
|
Exercise / conversionCommon Stock | 16,000 | $22.95 | $367,200.00 |
DisclosureSEC source: 0001062993-24-014847 · form4.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2024 Filed Aug 6, 2024 20:23 UTC |
Hippel JamesCFO
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 53,000 | $0.00 Strike: $31.26 | $0.00 |
DisclosureSEC source: 0001062993-24-014510 · form4.xml · derivative · entry 3 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,867 Underlying: Common Stock · 53,000 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 02, 2024 Filed Aug 6, 2024 20:23 UTC |
Hippel JamesCFO
|
Tax withholdingCommon Stock | 36,076 | $82.35 | $2,970,858.60 |
DisclosureSEC source: 0001062993-24-014510 · form4.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,926 Read SEC document |
| August 02, 2024 Filed Aug 6, 2024 20:23 UTC |
Hippel JamesCFO
|
Exercise / conversionCommon Stock | 53,000 | $31.26 | $1,656,780.00 |
DisclosureSEC source: 0001062993-24-014510 · form4.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:17 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $37.70 | $0.00 |
DisclosureSEC source: 0001062993-24-014366 · form4.xml · derivative · entry 3 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,392 Underlying: Common Stock · 14,000 shares Expires 2025-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:17 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 9,479 | $81.97 | $776,993.63 |
DisclosureSEC source: 0001062993-24-014366 · form4.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,942 Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:17 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 14,000 | $37.70 | $527,800.00 |
DisclosureSEC source: 0001062993-24-014366 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:31 UTC |
Hippel JamesCFO
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $31.26 | $0.00 |
DisclosureSEC source: 0001062993-24-014086 · form4.xml · derivative · entry 3 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,867 Underlying: Common Stock · 35,000 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:31 UTC |
Hippel JamesCFO
|
Tax withholdingCommon Stock | 24,282 | $77.77 | $1,888,411.14 |
DisclosureSEC source: 0001062993-24-014086 · form4.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,002 Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:31 UTC |
Hippel JamesCFO
|
Exercise / conversionCommon Stock | 35,000 | $31.26 | $1,094,100.00 |
DisclosureSEC source: 0001062993-24-014086 · form4.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,284 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The Reporting Person's direct ownership has been increased by 400 shares pursuant to a clerical error in a previous filing. Read SEC document |
| July 08, 2024 Filed Jul 10, 2024 20:35 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $22.95 | $0.00 |
DisclosureSEC source: 0001062993-24-013645 · form4.xml · derivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2024-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2024 Filed Jul 10, 2024 20:35 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionCommon Stock | 6,000 | $22.95 | $137,700.00 |
DisclosureSEC source: 0001062993-24-013645 · form4.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:17 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $22.95 | $0.00 |
DisclosureSEC source: 0001062993-24-010446 · form4.xml · derivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 4,000 shares Expires 2024-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:17 UTC |
HIGGINS JOHN LDirector
|
SaleCommon Stock | 4,000 | $83.84 | $335,377.20 |
DisclosureSEC source: 0001062993-24-010446 · form4.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,608 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 83.55 to 83.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:17 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionCommon Stock | 4,000 | $22.95 | $91,800.00 |
DisclosureSEC source: 0001062993-24-010446 · form4.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:34 UTC |
Klimovsky Judith V.Director
|
GrantStock Option (Right to Buy) · Derivative | 1,610 | $0.00 Strike: $73.46 | $0.00 |
DisclosureSEC source: 0001062993-24-009351 · form4.xml · derivative · entry 2 Klimovsky Judith V · CIK 0001762247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,610 Underlying: Common Stock · 1,610 shares Expires 2034-05-01 F1 · derivative.exercise_date: The option vests on the earlier of the one-year anniversary of the grant date or the date of Bio-Techne's annual meeting of shareholders. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:34 UTC |
Klimovsky Judith V.Director
|
GrantCommon Stock | 680 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-009351 · form4.xml · nonDerivative · entry 1 Klimovsky Judith V · CIK 0001762247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 680 Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:53 UTC |
Bohnen ShaneSVP - General Counsel
|
Exercise / conversionRestricted Stock Units · Derivative | 2,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-008111 · form4.xml · derivative · entry 3 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,519 Underlying: Common Stock · 2,259 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: 2,260 restricted stock units vest on 4/3/25 and 2,259 restricted stock units vest on 4/3/26. F2 · derivative.expiration_date: 2,260 restricted stock units vest on 4/3/25 and 2,259 restricted stock units vest on 4/3/26. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:53 UTC |
Bohnen ShaneSVP - General Counsel
|
Tax withholdingCommon Stock | 747 | $67.87 | $50,698.89 |
DisclosureSEC source: 0001062993-24-008111 · form4.xml · nonDerivative · entry 2 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,647 Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:53 UTC |
Bohnen ShaneSVP - General Counsel
|
Exercise / conversionCommon Stock | 2,259 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-24-008111 · form4.xml · nonDerivative · entry 1 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 20:04 UTC |
Nusse RoelandDirector
|
SaleCommon Stock | 10,400 | $76.98 | $800,627.36 |
DisclosureSEC source: 0001062993-24-006109 · form4.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,097 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.955 to $77.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:36 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
Tax withholdingCommon Stock | 1,111 | $68.54 | $76,147.94 |
DisclosureSEC source: 0001062993-24-002021 · form4.xml · nonDerivative · entry 1 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,759 F1 · balance_after: Includes 3,320 shares of restricted stock units for which the risk of forfeiture will lapse on 2/1/2025. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:35 UTC |
McManus MatthewPresident - DGS
|
GrantStock Option (Right to Buy) · Derivative | 15,902 | $0.00 Strike: $68.54 | $0.00 |
DisclosureSEC source: 0001062993-24-002020 · form4.xml · derivative · entry 4 McManus Matthew · CIK 0001908268 · President - DGS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,902 Underlying: Common Stock · 15,902 shares Expires 2031-02-01 F4 · derivative.exercise_date: Options to purchase 3,976 shares vest on 2/1/2025 and 2/1/2027, and options to purchase 3,975 shares vest on 2/1/2026 and 2/1/2028. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:35 UTC |
McManus MatthewPresident - DGS
|
GrantStock Option (Right to Buy) · Derivative | 7,951 | $0.00 Strike: $68.54 | $0.00 |
DisclosureSEC source: 0001062993-24-002020 · form4.xml · derivative · entry 3 McManus Matthew · CIK 0001908268 · President - DGS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,951 Underlying: Common Stock · 7,951 shares Expires 2031-02-01 F2 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:35 UTC |
McManus MatthewPresident - DGS
|
GrantRestricted Stock Units · Derivative | 13,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-002020 · form4.xml · derivative · entry 2 McManus Matthew · CIK 0001908268 · President - DGS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,861 Underlying: Common Stock · 13,861 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: 4,620 restricted stock units vest on 2/1/2025 and 2/1/2027, and 4,621 restricted stock units vest on 2/1/2026. F3 · derivative.expiration_date: 4,620 restricted stock units vest on 2/1/2025 and 2/1/2027, and 4,621 restricted stock units vest on 2/1/2026. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:35 UTC |
McManus MatthewPresident - DGS
|
GrantRestricted Stock Units · Derivative | 2,888 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-002020 · form4.xml · derivative · entry 1 McManus Matthew · CIK 0001908268 · President - DGS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,888 Underlying: Common Stock · 2,888 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:33 UTC |
Kelderman KimChief Operating Officer
|
GrantStock Options (Right to Buy) · Derivative | 51,890 | $0.00 Strike: $68.54 | $0.00 |
DisclosureSEC source: 0001062993-24-002018 · form4.xml · derivative · entry 19 Kelderman Kim · CIK 0001739054 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,890 Underlying: Common Stock · 51,890 shares Expires 2031-02-01 F11 · derivative.exercise_date: Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:33 UTC |
Kelderman KimChief Operating Officer
|
GrantStock Options (Right to Buy) · Derivative | 25,945 | $0.00 Strike: $68.54 | $0.00 |
DisclosureSEC source: 0001062993-24-002018 · form4.xml · derivative · entry 18 Kelderman Kim · CIK 0001739054 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,945 Underlying: Common Stock · 25,945 shares Expires 2031-02-01 F8 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:33 UTC |
Kelderman KimChief Operating Officer
|
GrantRestricted Stock Units · Derivative | 9,423 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-002018 · form4.xml · derivative · entry 17 Kelderman Kim · CIK 0001739054 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,423 Underlying: Common Stock · 9,423 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F8 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F8 · derivative.expiration_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 21:06 UTC |
Hippel JamesCFO
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 47,289 | $0.00 Strike: $31.26 | $0.00 |
DisclosureSEC source: 0001062993-23-023028 · form4.xml · derivative · entry 3 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,867 Underlying: Common Stock · 47,289 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 21:06 UTC |
Hippel JamesCFO
|
Tax withholdingCommon Stock | 32,966 | $77.42 | $2,552,227.72 |
DisclosureSEC source: 0001062993-23-023028 · form4.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,884 Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 21:06 UTC |
Hippel JamesCFO
|
Exercise / conversionCommon Stock | 47,289 | $31.26 | $1,478,254.14 |
DisclosureSEC source: 0001062993-23-023028 · form4.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 22:35 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
GrantRestricted Stock Units · Derivative | 19,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-020120 · form4.xml · derivative · entry 11 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,857 Underlying: Common Stock · 19,857 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9 · derivative.exercise_date: 9,929 restricted stock units vest on 11/1/2024 and 9,928 restricted stock units vest on 11/1/2025. F9 · derivative.expiration_date: 9,929 restricted stock units vest on 11/1/2024 and 9,928 restricted stock units vest on 11/1/2025. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 22:35 UTC |
Hippel JamesCFO
|
GrantRestricted Stock Units · Derivative | 26,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-020119 · form4.xml · derivative · entry 16 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,318 Underlying: Common Stock · 26,318 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F10 · derivative.exercise_date: 13,159 restricted stock units vest on each of 11/1/2024 and 11/1/2025. F10 · derivative.expiration_date: 13,159 restricted stock units vest on each of 11/1/2024 and 11/1/2025. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 22:34 UTC |
Kelderman KimChief Operating Officer
|
GrantStock Options (Right to Buy) · Derivative | 38,252 | $0.00 Strike: $52.83 | $0.00 |
DisclosureSEC source: 0001062993-23-020118 · form4.xml · derivative · entry 16 Kelderman Kim · CIK 0001739054 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,252 Underlying: Common Stock · 38,252 shares Expires 2030-11-01 F11 · derivative.exercise_date: Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 22:34 UTC |
Kelderman KimChief Operating Officer
|
GrantCommon Stock | 14,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-020118 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,421 F1 · shares: Represents 14,196 shares of restricted stock for which risks of forfeiture lapse as to 4,732 shares on each of 11/1/2024, 11/1/2025 and 11/1/2026. Read SEC document |
| November 01, 2023 Filed Nov 9, 2023 21:23 UTC Amendment |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
GrantRestricted Stock Units · Derivative | 19,823 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-020427 · form4a.xml · derivative · entry 1 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,823 Underlying: Common Stock · 19,823 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · shares: This amendment is being filed solely to correct a typographical error in the number of restricted stock units granted. F3 · derivative.exercise_date: 9,912 restricted stock units vest on 11/1/2024 and 9,911 restricted stock units vest on 11/1/2025. F3 · derivative.expiration_date: 9,912 restricted stock units vest on 11/1/2024 and 9,911 restricted stock units vest on 11/1/2025. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:55 UTC |
Seth AlpnaDirector
|
GrantStock Options (Right to Buy) · Derivative | 3,937 | $0.00 Strike: $61.51 | $0.00 |
DisclosureSEC source: 0001062993-23-019858 · form4.xml · derivative · entry 6 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,937 Underlying: Common Stock · 3,937 shares Expires 2033-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/2023) or the date of Bio-Techne's 2024 annual meeting of shareholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.